179 related articles for article (PubMed ID: 33966346)
21. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.
Huang D; Li X; Wei Y; Xiu Z
Eur J Med Chem; 2012 Jun; 52():111-22. PubMed ID: 22465091
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P; Parikh PK; Vyas VK; Ghate MD
Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
[TBL] [Abstract][Full Text] [Related]
23. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
24. Computational identification of novel histone deacetylase inhibitors by docking based QSAR.
Nair SB; Teli MK; Pradeep H; Rajanikant GK
Comput Biol Med; 2012 Jun; 42(6):697-705. PubMed ID: 22521374
[TBL] [Abstract][Full Text] [Related]
25. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
Bressi JC; Jennings AJ; Skene R; Wu Y; Melkus R; De Jong R; O'Connell S; Grimshaw CE; Navre M; Gangloff AR
Bioorg Med Chem Lett; 2010 May; 20(10):3142-5. PubMed ID: 20392638
[TBL] [Abstract][Full Text] [Related]
26. Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors.
Kalyaanamoorthy S; Chen YP
J Mol Graph Model; 2013 Jul; 44():44-53. PubMed ID: 23732305
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
[TBL] [Abstract][Full Text] [Related]
28. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
[TBL] [Abstract][Full Text] [Related]
29. Sulforaphane-N-Acetyl-Cysteine inhibited autophagy leading to apoptosis via Hsp70-mediated microtubule disruption.
Hu Y; Zhou Y; Yang G; Wang Y; Zheng Z; Li J; Yan Y; Wu W
Cancer Lett; 2018 Sep; 431():85-95. PubMed ID: 29807114
[TBL] [Abstract][Full Text] [Related]
30. Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment.
Elmezayen AD; Kemal Y
Comput Biol Chem; 2021 Jun; 92():107491. PubMed ID: 33930743
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
Huang D; Li X; Sun L; Xiu Z; Nishino N
J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
[TBL] [Abstract][Full Text] [Related]
32. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.
Clarke JD; Hsu A; Yu Z; Dashwood RH; Ho E
Mol Nutr Food Res; 2011 Jul; 55(7):999-1009. PubMed ID: 21374800
[TBL] [Abstract][Full Text] [Related]
34. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
[TBL] [Abstract][Full Text] [Related]
35. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.
Myzak MC; Karplus PA; Chung FL; Dashwood RH
Cancer Res; 2004 Aug; 64(16):5767-74. PubMed ID: 15313918
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis and Evaluation of Novel 3/4-((Substituted benzamidophenoxy) methyl)-N-hydroxybenzamides/propenamides as Histone Deacetylase Inhibitors and Antitumor Agents.
Anh DT; Thuan NT; Hai PT; Huong LT; Yen NTK; Han BW; Park EJ; Choi YJ; Kang JS; Hue VTM; Han SB; Nam NH
Anticancer Agents Med Chem; 2019; 19(4):546-556. PubMed ID: 30426904
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
38. Sulforaphane Ameliorates Diabetes-Induced Renal Fibrosis through Epigenetic Up-Regulation of BMP-7.
Kong L; Wang H; Li C; Cheng H; Cui Y; Liu L; Zhao Y
Diabetes Metab J; 2021 Nov; 45(6):909-920. PubMed ID: 34082508
[TBL] [Abstract][Full Text] [Related]
39. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors.
Zhou H; Wang C; Ye J; Chen H; Tao R
Gene; 2017 Dec; 637():63-71. PubMed ID: 28939339
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors.
Zhang L; Wang X; Li X; Zhang L; Xu W
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):582-9. PubMed ID: 24059701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
